These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 10668853)
1. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Sata F; Sapone A; Elizondo G; Stocker P; Miller VP; Zheng W; Raunio H; Crespi CL; Gonzalez FJ Clin Pharmacol Ther; 2000 Jan; 67(1):48-56. PubMed ID: 10668853 [TBL] [Abstract][Full Text] [Related]
2. Novel mutations of CYP3A4 in Chinese. Hsieh KP; Lin YY; Cheng CL; Lai ML; Lin MS; Siest JP; Huang JD Drug Metab Dispos; 2001 Mar; 29(3):268-73. PubMed ID: 11181494 [TBL] [Abstract][Full Text] [Related]
3. Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4. Ball SE; Scatina J; Kao J; Ferron GM; Fruncillo R; Mayer P; Weinryb I; Guida M; Hopkins PJ; Warner N; Hall J Clin Pharmacol Ther; 1999 Sep; 66(3):288-94. PubMed ID: 10511065 [TBL] [Abstract][Full Text] [Related]
4. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online. Walker AH; Jaffe JM; Gunasegaram S; Cummings SA; Huang CS; Chern HD; Olopade OI; Weber BL; Rebbeck TR Hum Mutat; 1998; 12(4):289. PubMed ID: 10660343 [TBL] [Abstract][Full Text] [Related]
5. Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype. Lee SJ; Bell DA; Coulter SJ; Ghanayem B; Goldstein JA J Pharmacol Exp Ther; 2005 Apr; 313(1):302-9. PubMed ID: 15634941 [TBL] [Abstract][Full Text] [Related]
6. Mutation analysis of the human CYP3A4 gene 5' regulatory region: population screening using non-radioactive SSCP. Hamzeiy H; Vahdati-Mashhadian N; Edwards HJ; Goldfarb PS Mutat Res; 2002 Mar; 500(1-2):103-10. PubMed ID: 11890939 [TBL] [Abstract][Full Text] [Related]
7. Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations. Schirmer M; Toliat MR; Haberl M; Suk A; Kamdem LK; Klein K; Brockmöller J; Nürnberg P; Zanger UM; Wojnowski L Pharmacogenet Genomics; 2006 Jan; 16(1):59-71. PubMed ID: 16344723 [TBL] [Abstract][Full Text] [Related]
8. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Johansson I; Oscarson M; Yue QY; Bertilsson L; Sjöqvist F; Ingelman-Sundberg M Mol Pharmacol; 1994 Sep; 46(3):452-9. PubMed ID: 7935325 [TBL] [Abstract][Full Text] [Related]
9. Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. Ando Y; Tateishi T; Sekido Y; Yamamoto T; Satoh T; Hasegawa Y; Kobayashi S; Katsumata Y; Shimokata K; Saito H J Natl Cancer Inst; 1999 Sep; 91(18):1587-90. PubMed ID: 10491442 [No Abstract] [Full Text] [Related]
10. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. Dai D; Tang J; Rose R; Hodgson E; Bienstock RJ; Mohrenweiser HW; Goldstein JA J Pharmacol Exp Ther; 2001 Dec; 299(3):825-31. PubMed ID: 11714865 [TBL] [Abstract][Full Text] [Related]
11. The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population. Armstrong M; Fairbrother K; Idle JR; Daly AK Pharmacogenetics; 1994 Apr; 4(2):73-81. PubMed ID: 8081414 [TBL] [Abstract][Full Text] [Related]
12. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region. Westlind A; Löfberg L; Tindberg N; Andersson TB; Ingelman-Sundberg M Biochem Biophys Res Commun; 1999 May; 259(1):201-5. PubMed ID: 10334940 [TBL] [Abstract][Full Text] [Related]
13. More about: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. Rebbeck TR J Natl Cancer Inst; 2000 Jan; 92(1):76. PubMed ID: 10620637 [No Abstract] [Full Text] [Related]
14. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Yokota H; Tamura S; Furuya H; Kimura S; Watanabe M; Kanazawa I; Kondo I; Gonzalez FJ Pharmacogenetics; 1993 Oct; 3(5):256-63. PubMed ID: 8287064 [TBL] [Abstract][Full Text] [Related]
15. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. García-Martín E; Martínez C; Pizarro RM; García-Gamito FJ; Gullsten H; Raunio H; Agúndez JA Clin Pharmacol Ther; 2002 Mar; 71(3):196-204. PubMed ID: 11907494 [TBL] [Abstract][Full Text] [Related]
16. Some mutations of exon-7 in cytochrome P450 gene 3A4 and their effect on 6beta-hydroxylation of cortisol. Shchepotina EG; Vavilin VA; Goreva OB; Lyakhovich VV Bull Exp Biol Med; 2006 Jun; 141(6):701-3. PubMed ID: 17364054 [TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity. Westlind-Johnsson A; Hermann R; Huennemeyer A; Hauns B; Lahu G; Nassr N; Zech K; Ingelman-Sundberg M; von Richter O Clin Pharmacol Ther; 2006 Apr; 79(4):339-49. PubMed ID: 16580902 [TBL] [Abstract][Full Text] [Related]
18. Coexpression of genetically engineered fused enzyme between yeast NADPH-P450 reductase and human cytochrome P450 3A4 and human cytochrome b5 in yeast. Hayashi K; Sakaki T; Kominami S; Inouye K; Yabusaki Y Arch Biochem Biophys; 2000 Sep; 381(1):164-70. PubMed ID: 11019832 [TBL] [Abstract][Full Text] [Related]
19. [Cytochrome P450 2C19 gene polymorphism in four Chinese nationality populations]. Zhang S; Dong Z; Tang L; Zhou Q; Wu Z Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Feb; 19(1):52-4. PubMed ID: 11836688 [TBL] [Abstract][Full Text] [Related]
20. Cloning of CYP2J2 gene and identification of functional polymorphisms. King LM; Ma J; Srettabunjong S; Graves J; Bradbury JA; Li L; Spiecker M; Liao JK; Mohrenweiser H; Zeldin DC Mol Pharmacol; 2002 Apr; 61(4):840-52. PubMed ID: 11901223 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]